Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression

References

• Arnedo A, Espuelas S, and Irache JM. 2002. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 244:59–72.
   PubMed Web of Science ®Google Scholar
• Boulaiz H, Marchal JA, Prados J, Melguizo C, and Aranega A. 2005. Non-viral and viral vectors for gene therapy. Cell Mol Biol (Noisy - le-grand) 51:3–22.
   PubMed Web of Science ®Google Scholar
• Check E. 2005. A crucial test. Nat Med 11:243–244.
   PubMed Web of Science ®Google Scholar
• Chiu SJ, Ueno NT, and Lee RJ. 2004. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 97:357–369.
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, and Strebhardt K. 2005. Polo-like kinases and oncogenesis. Oncogene 24:267–276.
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, and Reddy EP. 2005. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7:275–286.
   PubMed Web of Science ®Google Scholar
• Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H, and Strebhardt K. 1994. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A 91:1736–1740.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ. 2006. Cancer statistics, 2006. CA Cancer J Clin 56:106–130.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, and Park JW. 2006. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732–6740.
   PubMed Web of Science ®Google Scholar
• Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, and Schubert D. 2003. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257:169–180.
   PubMed Web of Science ®Google Scholar
• Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, and Baum C. 2002. Murine leukemia induced by retroviral gene marking. Science 296:497.
   PubMed Web of Science ®Google Scholar
• Lin W, Garnett MC, Schacht E, Davis SS, and Illum L. 1999. Preparation and in vitro characterization of HSA-mPEG nanoparticles. Int J Pharm 189:161–170.
   PubMed Web of Science ®Google Scholar
• Liu X and Erikson RL. 2003. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100:5789–5794.
   PubMed Web of Science ®Google Scholar
• Liu X, Lei M, and Erikson RL. 2006. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26:2093–2108.
   PubMed Web of Science ®Google Scholar
• Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, Ong SE, Gammeltoft S, Carr SA, and Yaffe MB. 2007. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26:2262–2273.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, and Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284.
   PubMed Web of Science ®Google Scholar
• Marshall E. 2002. Clinical research. Gene therapy a suspect in leukemia-like disease. Science 298:34–35.
   PubMed Web of Science ®Google Scholar
• Marshall E. 2003. Gene therapy. Second child in French trial is found to have leukemia. Science 299:320.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Takakura Y, and Hashida M. 2005. Theoretical considerations involving the pharmacokinetics of plasmid DNA. Adv Drug Deliv Rev 57:675–688.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, and Benz CC. 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172–1181.
   PubMed Web of Science ®Google Scholar
• Prabha S and Labhasetwar V. 2004. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res 21:354–364.
   PubMed Web of Science ®Google Scholar
• Rhaese S, von Briesen H, Rubsamen-Waigmann H, Kreuter J, and Langer K. 2003. Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release 92:199–208.
   PubMed Web of Science ®Google Scholar
• Rolland A. 2005. Gene medicines: the end of the beginning? Adv Drug Deliv Rev 57:669–673.
   PubMed Web of Science ®Google Scholar
• Romano G. 2007. Current development of nonviral-mediated gene transfer. Drug News Perspect 20:227–231.
   PubMed Web of Science ®Google Scholar
• Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, and Ferris DK. 1997. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234:397–405.
   PubMed Web of Science ®Google Scholar
• Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, and Medema RH. 2000. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2:672–676.
   PubMed Web of Science ®Google Scholar
• Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, and Strebhardt K. 2006. Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo. Cancer Res 66:5836–5846.
   PubMed Web of Science ®Google Scholar
• Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, and Strebhardt K. 2004. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96:862–872.
   PubMed Web of Science ®Google Scholar
• Spankuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, and Langer K. 2008. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 10:223–234.
   PubMed Web of Science ®Google Scholar
• Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, and Strebhardt K. 2002a. Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells. J Natl Cancer Inst 94:1863–1877.
   PubMed Web of Science ®Google Scholar
• Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, von Minckwitz G, Kaufmann M, and Strebhardt K. 2002b. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21:3162–3171.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, and Desai N. 2005. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136–4143.
   PubMed Web of Science ®Google Scholar
• Steinhauser I, Spankuch B, Strebhardt K, and Langer K. 2006. Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials 27:4975–4983.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA, Walko CM, O’neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, and Claire DE. 2007. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 60:759–766.
   PubMed Web of Science ®Google Scholar
• Strebhardt K and Ullrich A. 2006. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321–330.
   PubMed Web of Science ®Google Scholar
• Vorburger SA and Hunt KK. 2002. Adenoviral gene therapy. Oncologist 7:46–59.
   PubMed Web of Science ®Google Scholar
• Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, and Langer K. 2004a. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12:461–471.
   PubMed Web of Science ®Google Scholar
• Wartlick H, Spankuch-Schmitt B, Strebhardt K, Kreuter J, and Langer K. 2004b. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Control Release 96:483–495.
   PubMed Web of Science ®Google Scholar
• Yuan J, Horlin A, Hock B, Stutte HJ, Rubsamen-Waigmann H, and Strebhardt K. 1997. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 150:1165–1172.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, and Maclachlan I. 2006. RNAi-mediated gene silencing in non-human primates. Nature 441:111–114.
   PubMed Web of Science ®Google Scholar